+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Onchocerciasis Drug"

Onchocerciasis - Pipeline Insight, 2024 - Product Thumbnail Image

Onchocerciasis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Onchocerciasis, also known as river blindness, is a neglected tropical disease caused by a parasitic worm. It is spread by the bite of an infected blackfly and can cause severe itching, skin lesions, and vision loss. Treatment for onchocerciasis is primarily focused on the drug ivermectin, which is used to kill the adult worms and prevent further transmission. Ivermectin is typically administered in mass drug administration programs, which are designed to treat entire populations at risk of infection. In addition to ivermectin, other drugs are used to treat onchocerciasis, including doxycycline, albendazole, and diethylcarbamazine. These drugs are used to treat the symptoms of the disease, such as skin lesions, and to reduce the risk of transmission. The onchocerciasis drug market is highly competitive, with a number of companies offering treatments for the disease. These include Merck & Co., GlaxoSmithKline, Sanofi, Novartis, Pfizer, and Johnson & Johnson. Show Less Read more